FASN and hepatocellular carcinoma: Zhi‐Qiang Meng and colleagues performed transcriptomic and metabolomic analyses and found that Bufalin, a classic Na‐K‐ATPase (NKA) inhibitor, inhibits HCC lipogenesis and tumorigenesis by regulating the ATP1A1/CA2 axis to downregulate SREBP1/FASN/ACLY [101].